Regeneron Pharmaceuticals Inc
REGN XNAS
$775.84
-17.96 (-2.26%)
▼
15-min delayed
Open
$788.53
High
$788.58
Low
$774.21
Volume
240.2K
Market Cap
$81.72B
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.
Key Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 2026 | $4.29B | $1.30B | $12.62 |
| Q1 2026 | $3.61B | $727.20M | $6.99 |
| FY 2025 | $14.34B | $4.50B | $43.07 |
| Q3 2025 | $3.75B | $1.46B | $14.09 |
TickerDaily Coverage
Top Pre-Market Movers Today: 5 Stocks Making Biggest Moves Before the Bell
Market News
Sarah Mitchell · Aug 27, 2026
Five major stocks are making significant pre-market moves Thursday morning before the opening bell....
Healthcare Stocks This Week: XLV Outperforms on Rate Cut Bets — Weekly Roundup (Jun 29 – Jul 3, 2026)
Market News
David Brooks · Jul 3, 2026
The healthcare sector capped a record-breaking first half with a strong week as XLV rallied on...
Top Stocks Moving Pre-Market Today: NVDA, LLY, AMD Pre-Market Movers Before the Bell
Market News
Sarah Mitchell · Mar 6, 2026
Several major stocks are posting outsized pre-market moves ahead of today's opening bell, driven by...
View All Coverage →
Get REGN Alerts
Stay ahead with breaking news, price alerts, and expert analysis on Regeneron Pharmaceuticals Inc.
Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.